Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
← catalyst calendarNCT06408259 · readout in 1,696 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
194estimated
Sites
33
Countries
Australia, Italy, Mexico +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-08 | actual | When the study began enrolling |
| Primary completion | 2031-04-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-07-13 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Sclerosis, Relapsing-Remitting
Interventions
- Drug: Ozanimod
- Drug: Fingolimod
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized relapse rate (ARR)
measured Up to 2 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed